Navigation Links
ImmuLisa™ anti-gliadin(AGA)IgA Kit

ProductsImmuLisa™ anti-gliadin(AGA)IgA Kit
Company IMMCO Diagnostics
Item ImmuLisa™ anti-gliadin(AGA)IgA Kit
Features 
Description An enzyme-linked immuno-sorbent assay for the detection and quantitation of anti-tissue Transglutaminase in serum of patients with Celiac Disease and Dermatitis Herpetiformis.
Info IMMCO Diagnostics
Customer Service: (800) 537-8378
Web site: http://www.immcodiagnostics.com

Related medicine products :

1. ImmuLisa™ anti-gliadin-IgG Kit
2. ImmuLisa™ IgA-ACA anti-Cardiolipin Antibody (ACA) Kit
3. ImmuLisa™ IgG-ACA anti-Cardiolipin Antibody (ACA) Kit
4. ImmuLisa™ IgM-ACA anti-Cardiolipin Antibody (ACA) Kit
5. ImmuLisa™ anti-2-GP1 IgG Kit
6. ImmuLisa™ anti-2-GP1 IgM Kit
7. ImmuLisa™ Rheumatoid Factor IgA Kit
8. ImmuLisa™ Rheumatoid Factor IgM (RF) Kit
9. ImmuLisa™ Rheumatoid Factor Screen Kit
10. ImmuLisa™ anti-Glomerular Basement Membrane (GBM) Antibody Kit
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products:
(Date:5/19/2013)... People in Minnesota have a great option to get in ... Day Fat Loss Formula. The best part is people ... home. The product sells for $135 dollars and is an ... http://altmanfitness.com/28-day-fat-loss-formula/ , “Bikini season is almost here. People ... using the 28 Day Fat Loss Formula they will be ...
(Date:5/19/2013)... City, Utah (PRWEB) May 19, 2013 ... information on small business health insurance . ... to traditional employer sponsored health benefits, is the ... and health reimbursement arrangements . , ... start-ups, and the self-employed intrinsically know the value ...
(Date:5/19/2013)... May 19, 2013 These molecular ... US, UK, Spain, Japan, Italy, Germany and France:, ... molecular diagnostics laboratory practice, as well as key ... significant market impact during the next five years. ... and biochip technologies, test formats, detection methodologies, trends ...
(Date:5/19/2013)... (PRWEB) May 19, 2013 Americans live ... to the newest American Veterinary Medical Association (AVMA) U.S. ... American dog owners consider their dog a member of ... had said as much five years earlier. , According ... value of the national income dedicated to pets has ...
(Date:5/19/2013)... Las Vegas, Nevada (PRWEB) May 19, 2013 ... travel agency , is proud to announce the launch ... Music Awards at the MGM Grand on 5/19/2013. Consumers ... the all new special pricing available on VegasHotelEscapes.com's website. ... guarantee that they beat any competitors price. , Vegas ...
Breaking Medicine News(10 mins):Health News:Zane Benefits Publishes New Information on Small Business Health Insurance 2Health News:Zane Benefits Publishes New Information on Small Business Health Insurance 3Health News:Molecular Diagnostics Market - US, UK, Spain, Japan, Italy, Germany & France Analysis in New Research Report at ReportsnReports.com 2Health News:Molecular Diagnostics Market - US, UK, Spain, Japan, Italy, Germany & France Analysis in New Research Report at ReportsnReports.com 3Health News:Molecular Diagnostics Market - US, UK, Spain, Japan, Italy, Germany & France Analysis in New Research Report at ReportsnReports.com 4Health News:Dogs Becoming Part of the Family: Dog Bite Injuries Decreasing 2Health News:Dogs Becoming Part of the Family: Dog Bite Injuries Decreasing 3
... Feb. 10 During scheduled visits to Members of ... Homecare and its members will urge Congress and the ... the Medicare Anti-Fraud Legislative Plan. Developed by the ... tough, effective measures to stop waste, fraud and abuse ...
... researchers say , , TUESDAY, Feb. 10 (HealthDay News) -- ... even bother to use them because they,re difficult to ... are allowing the brain to communicate directly with artificial ... banana and fold laundry. , "In the simplest terms, ...
... even if you stop taking the drug, study finds , , ... aspirin or other nonsteroidal anti-inflammatory drugs (NSAIDs) appears to reduce ... cancer. , That,s the conclusion of a new study of ... clear, and arguably proven, that NSAID drugs do interfere with ...
... of Potential Surrogate Endpoints of Long-Term Survival in Prostate ... distant metastases 3 years after the start of treatment ... with early prostate cancer. , Prostate cancer is a ... history of the disease makes evaluation of new therapies ...
... percent as a result of My Health programLOS ... Institute (IBI) and the National Business Coalition on ... the 2009 IBI/NBCH Healthy Workforce Productivity Award at ... 9-11 in Los Angeles. The award, sponsored by ...
... to have an effect on whether a patient with terminal ... by researchers at Beth Israel Deaconess Medical Center (BIDMC). Published ... the American Geriatrics Society ( JAGS ), the findings ... services less frequently than do whites and Hispanics. , According ...
Cached Medicine News:Health News:American Association for Homecare Proposes to Congress a Medicare Anti-Fraud Action Plan that Includes Increased Penalties, Site Inspection, and Tough Standards 2Health News:American Association for Homecare Proposes to Congress a Medicare Anti-Fraud Action Plan that Includes Increased Penalties, Site Inspection, and Tough Standards 3Health News:American Association for Homecare Proposes to Congress a Medicare Anti-Fraud Action Plan that Includes Increased Penalties, Site Inspection, and Tough Standards 4Health News:New Technology May Boost Artificial Arms 2Health News:Long-Term Aspirin Use Seems to Protect Against Colorectal Lesions 2Health News:Long-Term Aspirin Use Seems to Protect Against Colorectal Lesions 3Health News:Also in the Feb. 10 JNCI 2Health News:Also in the Feb. 10 JNCI 3Health News:Also in the Feb. 10 JNCI 4Health News:Also in the Feb. 10 JNCI 5Health News:Nationwide Receives IBI/NBCH Healthy Workforce Productivity Award 2Health News:Nationwide Receives IBI/NBCH Healthy Workforce Productivity Award 3Health News:Study finds race and ethnicity affect use of hospice services among patients with advanced cancer 2
(Date:5/17/2013)... BOSTON , May 17, 2013  TechAtlas ... update for their competitive landscape map for the ... highlights over 90 international companies with drugs and ... addressing CKD and its sequelae. ... include: , hypertension - renal denervation ...
(Date:5/17/2013)... Fuse Science, Inc. (OTCQB: DROP), ( www.fusescience.com ) ... new, patent-pending technologies poised to redefine how consumers receive energy, ... a business update teleconference and webcast for shareholders and the ... 4:30 PM ET. Fuse Science, Inc. CEO, ... and will be joined by Rubin Hanan ...
(Date:5/17/2013)... -- Sanofi (EURONEXT: SAN and NYSE: SNY ) announced ... , examining the selective JAK2 inhibitor SAR302503 for myelofibrosis ... The primary endpoint assessed the proportion of patients achieving ... in previous trials, the most common adverse events were ... presented at an upcoming medical congress. ...
Breaking Medicine Technology:TechAtlas Group Releases Innovative Chronic Kidney Disease Landscape Map 2Fuse Science, Inc. to Hold Business Update Webcast and Teleconference on May 22nd 2Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis 2Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis 3Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis 4Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis 5Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis 6